System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Justin M Watts is an expert in Hematology at Sylvester Comprehensive Cancer Center (United States). As of October 2026, ScienceLeadR ranks Justin M Watts in the top 1% of experts worldwide for Leukemia. Justin M Watts has authored 393 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 4 of them ongoing. SLR score: 1,716 (community average: 125). How the SLR is computed.

LeadR Profile

Justin M Watts Sylvester Comprehensive Cancer Center United States
1 716 ScienceLeadR Reputation 1716

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026
Source: PubMed

University of Miami Health System

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 393

Citations

Citations: 11 085 1st author: 71 Last author: 87 Unique author: 15

Main journals

Blood 86
CL LYMPH MYELOM LEUK 18
J Clin Oncol 15
Br J Surg 14
Aust N Z J Surg 13

Best Journals

J Clin Oncol 14
Lancet 4
J Hematol Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Concurrent BCR::ABL1 and SET::NUP214 fusions in blast-phase chronic myeloid leukemia.
PMID 42700630 — dasatinib, leukemia, leukemia, myeloid, blast crisis, leukemia, myelogenous, chronic, bcr-abl positive		Cancer Genet20260
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
PMID 42644317 — myelodysplastic syndromes, poly(adp-ribose) polymerase inhibitors, poly(adp-ribose) polymerases, oxidoreductases, isocitrate dehydrogenase, ribose, poly adenosine diphosphate ribose, adenosine diphosphate ribose		Br J Haematol20260
Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.
PMID 42599122 — azacitidine, transplants		Eur J Haematol20260
Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
PMID 42521244 — precursor cell lymphoblastic leukemia-lymphoma, hematology, dasatinib, leukemia, chromosomes, philadelphia chromosome		Am J Hematol20260
Menin inhibitors as a treatment for acute leukemia: from bench to the clinic.
PMID 42519171 — leukemia, therapeutics		Blood Neoplasia20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 1 6
Phase 1/Phase 2 6
Phase 2 6
Phase 3 1
Phase 4 1

By status:

Recruiting 7
Completed 6
Terminated 3
Active not recruiting 2
Suspended 1
Unknown 1

By type:

Interventional 20

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 4
multicentricup10 11

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Olutasidenib Venetoclax and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
NCT06782542 — injections, fasting, stomach, induction chemotherapy, leukemia, tablets, drug therapy, leukemia, myeloid, acute, azacitidine, capsules, leukemia, myeloid, therapeutics, meals, mutation, chemotherapy		Phase 2Recruiting2026
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
NCT06504459 — cells, growth, bone marrow, blood, radionuclide angiography, heart, spinal puncture, neoplasms, multiple chronic conditions, gated blood-pool imaging, cytarabine, leukemia, angiography, biopsy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, cladribine, work, echocardiography, specimen handling, therapeutics, punctures, pyrimidinones, leukemia, monocytic, acute, radionuclide ventriculography, cytosine, spine, bone and bones		Phase 2Recruiting2025
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
NCT06311227 — cells, leukemia, hairy cell, bone marrow, blood, tomography, spinal puncture, neoplasms, magnetic resonance imaging, leukemia, biopsy, specimen handling, therapeutics, punctures, spine, bone and bones		Phase 2Active not recruiting2024
A Phase 1 2 Study of Enzomenib (DSP 5336) in Patients With Acute Leukemia (Horizen 1)
NCT04988555 — cells, precursor cell lymphoblastic leukemia-lymphoma, myelodysplastic syndromes, voriconazole, fluconazole, hematologic neoplasms, lymphoma, leukemia, drug therapy, leukemia, myeloid, acute, leukemia, lymphoid, azacitidine, multiple myeloma, leukemia, myeloid, azoles, mutation, chemotherapy		Phase 1/Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS